This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
The innocent bearer of unwelcome news often suffers blame by association. Often, when speaking to groups of physicians about the new cephalosporin antibiotics, I sense waves of hostility lapping at me as if I were personally responsible for the inundations of those agents that we are wallowing in. It is frustrating because there are too many of them, and they are too much alike, both in names and in their antimicrobial spectra—cefotaxime, cefuroxime, ceforanide, cefmenoxime, ceftazidime, cefoperazone, cefsulodin, ceftriaxone, and the list goes on. If infectious diseases did not already exist as a subspecialty, it would have to be created so that a select group of individuals could devote all their time and all the memory storage areas in their brains to cataloging the names and characteristics of these drugs. Moxalactam has the virtue of not sounding like all the others but, just to complicate that fact, moxalactam is known
NELSON JD. A Primer for Pediatricians on New Cephalosporin Antibiotics. Am J Dis Child. 1983;137(11):1041–1042. doi:10.1001/archpedi.1983.02140370003001
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: